ClinicalTrials.gg
RecruitingNCT07443696STB-XTR-003Updated Nov 12, 2026

PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy

A Phase 2 interventional study of Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging and Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging in Ischemic Cardiomyopathy and Heart Failure, sponsored by Sinotau Pharmaceutical Group. Recruiting at 3 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sinotau Pharmaceutical Group · Phase 2, Interventional, and Diagnostic

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
201st of 246
40 · median 127
Started
2025
with 35 others
Phase 2
22 of 375
6 open now
Primary completion
2026-12
later than 82 of 181 live
Registered
327th of 375
by date

Among the 375 studies in Heart Failure with a site in China, this one is the 201st largest by planned enrollment of the 246 interventional ones that give a count, is one of 36 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 82 of the 181 other live ones, and was the 327th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial. A total of 40-60 patients will be enrolled and randomized into two study groups as: fasting XTR003/18F-FDG group and glucose-loaded group at a 1:1 ratio. Each group will receive resting myocardial perfusion imaging (MPI) combined with metabolic PET imaging to evaluate myocardial metabolic activity and myocardial viability. Segmental perfusion abnormality, metabolic activity and myocardial viability will be analyzed according to the standard approaches in Nuclear Cardiology. Regional and global left ventricular function will be assessed with cardiac MRI and echocardiography prior to and post the completion of full revascularization within 6-month time point. A repeated resting MPI will also be performed to assess the improvement of perfusion abnormality.

All study subjects will undergo 6 months follow-up for major adverse cardiac events (MACE).

03

Conditions studied

  • Ischemic Cardiomyopathy
  • Heart Failure

Browse trials for

Keywords

  • 18F-FDG
  • XTR003
  • position emission tomography
  • myocardial metabolic imaging
  • myocardial viability
  • ischemic cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 85 years, regardless of gender.
  2. Diagnosed with ischemic cardiomyopathy (ICM).
  3. significant coronary artery disease (CAD).
  4. Left ventricular systolic dysfunction, with ranging from >20% to ≤40%
  5. Assessed by a team of cardiac surgeons/operators as suitable for complete revascularization.
  6. Capable of effective communication with the investigators, able to understand and comply with the clinical study requirements, voluntarily participate in the study, and provide written after being fully informed.

Exclusion criteria

Exclusion Criteria:

  1. Decompensated heart failure within 48 hours prior to enrollment.
  2. Recent ST-segment elevation myocardial infarction (STEMI) within less than 4 weeks.
  3. Left ventricular aneurysm.
  4. Judged by the investigator as unable to complete PET examination.
  5. Severe renal insufficiency.
  6. Severe hepatic insufficiency.
  7. Subjects with fever or active infectious diseases who are assessed by the investigator as unsuitable for study participation.
  8. Pregnant or lactating women.
  9. to magnetic resonance imaging (MRI), such as claustrophobia or intracorporeal metallic implants.
  10. Subjects with mental disorders or poor compliance.
  11. Significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv per year) or exposure to radioactive substances/ionizing radiation for therapeutic or research purposes within the past 10 years.
  12. Other circumstances deemed by the investigator as unsuitable for trial participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Fasting XTR003/ ¹⁸F-FDG PET

    Fasting XTR003 and ¹⁸F-FDG PET combined with myocardial metabolic imaging

    Drug: Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging

  • Active comparator
    Glucose-modulated ¹⁸F-FDG PET

    Glucose-modulated ¹⁸F-FDG PET Myocardial Metabolic Imaging

    Drug: Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging

Interventions

  • DrugFasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging

    Fasting XTR003 / ¹⁸F-FDG PET myocardial metabolic imaging

  • DrugGlucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging

    Glucose loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging

06

What researchers measure

Primary outcomes

  1. the sensitivity and specificity of the experimental group and control group

    Using the recoverable left-ventricular wall motion abnormality at 6 months post full revascularization as the reference standard to study the sensitivity and specificity of myocardial viability for predicting functional recovery in the experimental group and control group.

    Time frame: 6 months

Secondary outcomes

  1. Myocardial perfusion-metabolism imaging parameters (segmental level)

    include the following three items: 1. summed rest score 2. summed FDG score 3. summed rest score minus summed FDG score

    Time frame: 6 months

  2. Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization

    Left ventricular ejection fraction (LVEF, %)

    Time frame: 6 months

  3. Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization

    Left ventricular end-diastolic diameter (LVEDD)

    Time frame: 6 months

  4. Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization

    Left ventricular end-systolic diameter (LVESD)

    Time frame: 6 months

  5. Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization

    Left ventricular end-diastolic volume (LVEDV, mL)

    Time frame: 6 months

  6. Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization

    Left ventricular end-systolic volume (LVESV, mL)

    Time frame: 6 months

  7. Changes in New York Heart Association Functional Classification (NYHA)

    Time frame: 6 months

  8. Duration Required for PET Myocardial Metabolic Imaging in the Two Groups (min)

    Time frame: day 1

  9. PET Myocardial Metabolic Imaging Quality

    Time frame: day 1

  10. Resting MPI of perfusion abnormality

    Time frame: 6 months

  11. Major adverse cardiac events (MACE)

    Time frame: 6 months

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Mar 2, 2026
StartActual
Dec 18, 2025
Primary completionEst.
Dec 31, 2026was Aug 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 31, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Aug 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07443696
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Dec 18, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Tao Liu
Contact
tao.liu1@sinotau.com
+86-18101131863

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion